GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it may not be as potent as injectable GLP-1 drugs on the market.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...